Go Back to All Products
Showing all 2 results
Indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have specific epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test
Reminder: Food, Drugs, Devices, and Cosmetics Act prohibits dispensing w/o prescription.
For the treatment of adult patients with HER2 positive metastatic breast cancer (MBC).